ClinicalTrials.gg
CompletedNCT02054702Updated Dec 30, 2015Results posted

Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

A Phase 3 interventional study of Brexpiprazole and Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-12-30.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
16th of 28
97 · median 155
Started
2014
the only one that year
Phase 3
16 of 28
none open now
Registered
19th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 16th largest by enrollment, is the only one that started in 2014, is one of 16 in phase 3, and was the 19th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Mental Disorders
  • Psychotic Disorders
  • Antipsychotic
  • Cognitive testing
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 years of age, inclusive, at the time of with a diagnosis of schizophrenia as defined by the , Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) for Schizophrenia and Psychotic Disorders Studies
  • Would benefit from hospitalization or continued hospitalization for treatment of a current acute relapse of schizophrenia at trial entry
  • Are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by all of the following:
  • Positive and Negative Syndrome Scale (PANSS) Total Score of ≥ 80
  • Score of ≥ 4 on two or more of the following PANSS items at screening: hallucinatory behavior, unusual thought content, conceptual disorganization, or suspiciousness
  • Clinical Global Impression - Severity of Illness Scale (CGI-S) score ≥ 4 (moderately ill)

Exclusion criteria

Exclusion Criteria:

  • Are presenting with a first episode of schizophrenia based on the clinical judgment of the investigator
  • Have been hospitalized > 21 days for the current acute episode at the time of the baseline visit
  • Have a current Axis I diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or other cognitive disorders; also borderline, paranoid, histrionic, schizotypal, schizoid, antisocial personality disorders or mental retardation.
  • Improvement of ≥ 20% in total PANSS score between the screening and baseline assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally

    Drug: Brexpiprazole

  • Experimental
    Aripiprazole

    Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally

    Drug: Aripiprazole

Interventions

  • Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally

  • Up to 20 mg/day, once daily dose, tablets, orally

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change From Baseline in Cognitive Test Battery Composite Score

    The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

    Time frame: Baseline to Week 6

  2. Change From Baseline in Cognitive Test Battery of Early Phase Battery Score

    The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement. The cognitive test early phase battery was analyzed; tasks included Groton Maze Learning Task, Detection Task, Identification Task, and One Card Learning Task.

    Time frame: Baseline to Week 6

  3. Change From Baseline in Cognitive Test Battery Scores of Groton Maze Learning (GML)

    The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

    Time frame: Baseline to Week 6

  4. Change From Baseline in Cognitive Test Battery Scores of Detection Task

    The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

    Time frame: Baseline to Week 6

  5. Change From Baseline in Cognitive Test Battery Scores of Identification Task

    The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

    Time frame: Baseline to Week 6

  6. Change From Baseline in Cognitive Test Battery Scores of One Card Learning Task

    The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

    Time frame: Baseline to Week 6

  7. Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline to Week 6

  8. Mean Change in Clinical Global Impression-Improvement (CGI-I) Score at Week 6

    The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Baseline to Week 6

  9. Response Rate by Study Week

    The response rate was defined as reduction of ≥30% from Baseline in PANSS Total Score or CGI-I score of of 1 (very much improved) or 2 (much improved).

    Time frame: Baseline to Week 6

  10. Change From Baseline to Week 6 in Specific Levels of Functioning Scale (SLOF) Total Score

    The SLOF questionnaire used in this trial consisted of 30 items grouped into 4 areas: interpersonal relationships, social acceptability, activities, and work skill. The SLOF correlates with a subject's quality of life. Each of the questions in the domains is rated on a 5-point Likert scale ranging from 1 "not well at all" to 5 "very well". The possible total score range for SLOF is from 30 to 150, higher score indicating better overall functioning of the participant.

    Time frame: Baseline to Week 6

  11. Change From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11 Item) Total Score

    The BIS-11, a subject-rated scale designed to assess impulsive personality traits, was administered at the baseline and Week 6 visits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). The scores provided information to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and 3 second-order factors (motor impulsiveness, nonplanning impulsiveness, and attentional impulsiveness). The total score ranged from 30 to 120, higher scores indicate better personality trait.

    Time frame: Baseline to Week 6

07

Results

Posted Dec 1, 2015

Participant flow

The trial was conducted in 97 participants at 19 trial sites in United States.

Participant flow — Overall Study
MilestoneBrexpiprazoleAripiprazole
Started6433
Completed4021
Not completed2412
Withdrew: Lost to follow-up35
Withdrew: Adverse event31
Withdrew: Met withdrawal criteria41
Withdrew: Physician decision01
Withdrew: Withdrawal by subject144

Outcome measures

PrimaryChange From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
Units on a scaleBrexpiprazoleAripiprazole
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score-22.9 ± 1.7-19.4 ± 2.4
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
  • Aripiprazole · Mixed Models Analysis · p = <0.0001Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryChange From Baseline in Cognitive Test Battery Composite Score

The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · z-score
Change From Baseline in Cognitive Test Battery Composite Score
z-scoreBrexpiprazoleAripiprazole
Change From Baseline in Cognitive Test Battery Composite Score0.045 ± 0.056-0.024 ± 0.081
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.4244Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
  • Aripiprazole · Mixed Models Analysis · p = 0.7623Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryChange From Baseline in Cognitive Test Battery of Early Phase Battery Score

The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement. The cognitive test early phase battery was analyzed; tasks included Groton Maze Learning Task, Detection Task, Identification Task, and One Card Learning Task.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · z-score
Change From Baseline in Cognitive Test Battery of Early Phase Battery Score
z-scoreBrexpiprazoleAripiprazole
Change From Baseline in Cognitive Test Battery of Early Phase Battery Score-0.010 ± 0.0630.113 ± 0.091
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.8759Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
  • Aripiprazole · Mixed Models Analysis · p = 0.2176Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryChange From Baseline in Cognitive Test Battery Scores of Groton Maze Learning (GML)

The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · z-score
Change From Baseline in Cognitive Test Battery Scores of Groton Maze Learning (GML)
z-scoreBrexpiprazoleAripiprazole
Change From Baseline in Cognitive Test Battery Scores of Groton Maze Learning (GML)0.7 ± 3.7-4.6 ± 5.1
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.8420Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
  • Brexpiprazole vs Aripiprazole · Mixed Models Analysis · p = 0.3781Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryChange From Baseline in Cognitive Test Battery Scores of Detection Task

The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · z-score
Change From Baseline in Cognitive Test Battery Scores of Detection Task
z-scoreBrexpiprazoleAripiprazole
Change From Baseline in Cognitive Test Battery Scores of Detection Task0.024 ± 0.018-0.029 ± 0.026
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.1807Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
  • Aripiprazole · Mixed Models Analysis · p = 0.2802Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryChange From Baseline in Cognitive Test Battery Scores of Identification Task

The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · z-score
Change From Baseline in Cognitive Test Battery Scores of Identification Task
z-scoreBrexpiprazoleAripiprazole
Change From Baseline in Cognitive Test Battery Scores of Identification Task-0.002 ± 0.011-0.011 ± 0.016
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.8622Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
  • Aripiprazole · Mixed Models Analysis · p = 0.4848Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryChange From Baseline in Cognitive Test Battery Scores of One Card Learning Task

The cognitive test battery contains 8-tasks, including the Detection Task (DET, speed of processing), Identification Task (IDN, attention/vigilance), One Card Learning Task (OCL, visual learning), One-back Memory Task (ONB, working memory), Two Back Task (TWOB, working memory), the Groton Maze Learning Task (GML, problem solving/error monitoring), Social Emotional Cognition Task (SECT, social cognition), International shopping List Task (ISL, verbal learning and memory). The results of each domain on the cognitive test battery were calculated into Z-scores, where the healthy control mean was set to zero and the standard deviation to 1. A composite score was generated, with higher values representing better cognitive performance. The composite score is then the mean of z-scores for appropriate tasks where z-score = - 1 × z-score for DET, GML, IDN and ONB to correct for the direction of improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · z-score
Change From Baseline in Cognitive Test Battery Scores of One Card Learning Task
z-scoreBrexpiprazoleAripiprazole
Change From Baseline in Cognitive Test Battery Scores of One Card Learning Task0.003 ± 0.0180.000 ± 0.027
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.8588Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
  • Aripiprazole · Mixed Models Analysis · p = 0.9928Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score

The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
Units on a scaleBrexpiprazoleAripiprazole
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score-1.6 ± 0.1-1.3 ± 0.2
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
  • Aripiprazole · Mixed Models Analysis · p = <0.0001Mixed model repeated measures method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Change in Clinical Global Impression-Improvement (CGI-I) Score at Week 6

The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Baseline to Week 6
Reported as:
Mean · Units on a scale
Mean Change in Clinical Global Impression-Improvement (CGI-I) Score at Week 6
Units on a scaleBrexpiprazoleAripiprazole
Mean Change in Clinical Global Impression-Improvement (CGI-I) Score at Week 62.5 ± 0.92.7 ± 1.0
SecondaryResponse Rate by Study Week

The response rate was defined as reduction of ≥30% from Baseline in PANSS Total Score or CGI-I score of of 1 (very much improved) or 2 (much improved).

Time frame:
Baseline to Week 6
Reported as:
Number · percentage of participants
Response Rate by Study Week
percentage of participantsBrexpiprazoleAripiprazole
Response Rate by Study Week60.948.5
SecondaryChange From Baseline to Week 6 in Specific Levels of Functioning Scale (SLOF) Total Score

The SLOF questionnaire used in this trial consisted of 30 items grouped into 4 areas: interpersonal relationships, social acceptability, activities, and work skill. The SLOF correlates with a subject's quality of life. Each of the questions in the domains is rated on a 5-point Likert scale ranging from 1 "not well at all" to 5 "very well". The possible total score range for SLOF is from 30 to 150, higher score indicating better overall functioning of the participant.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Week 6 in Specific Levels of Functioning Scale (SLOF) Total Score
Units on a scaleBrexpiprazoleAripiprazole
Change From Baseline to Week 6 in Specific Levels of Functioning Scale (SLOF) Total Score7.5 (4.0 to 10.9)6.0 (1.2 to 10.8)
Statistical analysis
  • Brexpiprazole · ANCOVA · p = <0.0001The analysis of covariance (ANCOVA) model with treatment group and total score at baseline as covariate was used for change from baseline comparisons.
  • Aripiprazole · Mixed Models Analysis · p = <0.0001The ANCOVA model, with treatment group as main effect and total score at baseline as covariate, was used for change from baseline comparisons.
SecondaryChange From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11 Item) Total Score

The BIS-11, a subject-rated scale designed to assess impulsive personality traits, was administered at the baseline and Week 6 visits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). The scores provided information to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and 3 second-order factors (motor impulsiveness, nonplanning impulsiveness, and attentional impulsiveness). The total score ranged from 30 to 120, higher scores indicate better personality trait.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11 Item) Total Score
Units on a scaleBrexpiprazoleAripiprazole
Change From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11 Item) Total Score-2.6 (-5.0 to -0.1)-0.1 (-3.5 to 3.3)
Statistical analysis
  • Brexpiprazole · ANCOVA · p = 0.0392The ANCOVA model, with treatment group as main effect and total score at baseline as covariate, was used for change from baseline comparisons.
  • Aripiprazole · ANCOVA · p = 0.9716The ANCOVA model, with treatment group as main effect and total score at baseline as covariate, was used for change from baseline comparisons.

Adverse events

Collected over Adverse events were reported from the signing of informed consent throughout the 6-week treatment period until the follow-up visit 30 days (+2) after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole—3/64 (4.7%)36/64 (56.3%)
Aripiprazole—1/33 (3%)21/33 (63.6%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazoleAripiprazole
PresynscopeNervous system disorders0/641/33
Acute hepatitis BInfections and infestations1/640/33
ConvulsionNervous system disorders1/640/33
SchizophreniaPsychiatric disorders1/640/33
Most frequent other events
Showing 10 of 13
Most frequent other events
EventBrexpiprazoleAripiprazole
AkathisiaNervous system disorders6/647/33
HeadacheNervous system disorders5/644/33
Weight increasedInvestigations6/643/33
DyspepsiaGastrointestinal disorders5/643/33
ConstipationGastrointestinal disorders3/643/33
Dry mouthGastrointestinal disorders5/642/33
NauseaGastrointestinal disorders4/641/33
Pain in extremityMusculoskeletal and connective tissue disorders4/641/33
DiarrhoeaGastrointestinal disorders3/642/33
Back painMusculoskeletal and connective tissue disorders2/642/33

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BrexpiprazoleArpiprazoleTotal
Mean42.2 ± 10.142.1 ± 10.442.2 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)BrexpiprazoleArpiprazoleTotal
Female181028
Male462369
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Jun 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 6 months after primary completion. A results delay was requested in Jun 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2014
First posted
Feb 4, 2014
Start
Feb 2014
Primary completionActual
Jun 2014
CompletionActual
Jul 2014
Results delay requested
Jun 17, 2015
Results first posted
Dec 1, 2015
Last update
Dec 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02054702
Responsible party
Sponsor
First posted
Feb 4, 2014
Start date
Feb 2014
Primary completion
Jun 2014
Completion
Jul 2014
Results posted
Dec 1, 2015
Last update
Dec 30, 2015

Study contacts

Junichi Hashimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brexpiprazole · Aripiprazole

Start the discussion